Compare MYSZ & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | BBLG |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Israel | United States |
| Employees | N/A | 2 |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.5M |
| IPO Year | 2017 | N/A |
| Metric | MYSZ | BBLG |
|---|---|---|
| Price | $0.45 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.2K | ★ 47.6K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,000.00 | N/A |
| Revenue This Year | $41.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.38 | $1.05 |
| 52 Week High | $1.65 | $4.13 |
| Indicator | MYSZ | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 37.22 |
| Support Level | $0.38 | $1.08 |
| Resistance Level | $0.50 | $1.38 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 30.00 | 13.16 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.